Annals of Hematology

, Volume 96, Issue 4, pp 597–603 | Cite as

Circulating microparticles and the risk of thromboembolic events in Egyptian beta thalassemia patients

  • Ilham Youssry
  • Nohair Soliman
  • Mona Ghamrawy
  • Rania Mohamed Samy
  • Amal Nasr
  • Mohamed Abdel Mohsen
  • Mohamed ElShahaat
  • Rayan Bou Fakhredin
  • Ali Taher
Original Article


The presence of elevated numbers of circulating microparticles (MPs) has been hypothesized to be responsible for the occurrence of thromboembolic events (TEEs) in thalassemic patients. Our aim is to evaluate the presence and the thrombotic risk of circulating MPs in thalassemia patients and to determine the difference in MPs between β-thalassemia major (β-TM) and thalassemia intermedia (TI). The percentage of the annexin-labeled MPs, platelet-derived MPs (PMPs), erythrocyte-derived MPs (RMPs), and endothelial-derived MPs (EMPs) was measured by flow cytometry, in 87 thalassemia patients (39 β-TM and 48 TI). By multiple regression analysis, we then assessed the various independent risk factors for the occurrence of TEE. The thalassemic patients who experienced TEE had a significantly higher platelet count, higher percentage of annexin-labeled MPs, and higher percentage of PMPs (p value = 0.014, 0.003, and 0.014, respectively). There was no significant difference between β-TM and TI patients at the level of any of the studied MPs. The predictive risk factors for TEE in thalassemic patients were splenectomy, total and direct bilirubin, the RMPs, and the EMPs (OR = 10.07 (CI = 3.7–27.1), 4.3 (CI = 2.1–8.7), 1.4 (CI = 1.5–6.2), 1.6 (CI = 1.1–2.2), 3.0 (CI = 1.9–4.9), respectively). In conclusion, the elevated numbers of circulating MPs is a risk factor for the TEE in thalassemia patients.


Thalassemia major Thalassemia intermedia Microparticles Hypercoagulable state 


Compliance with ethical standards

Patients and/or their guardians gave their informed consent, and the Institutional Review Board (IRB) approved the study.

Financial relationship:

This research had no financial support.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Martin A, Thompson AA (2013). Thalassemias. Pediatr Clin North Am 60:138391Google Scholar
  2. 2.
    Owens AP 3rd, Mackman N (2011) Microparticles in hemostasis and thrombosis. Circ Res 108:1284–1297CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Flaumenhaft R (2006) Formation and fate of platelet microparticles. Blood Cells Mol Dis 36:182–187CrossRefPubMedGoogle Scholar
  4. 4.
    Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L (2003) Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 102:2678–2683CrossRefPubMedGoogle Scholar
  5. 5.
    Van Beers EJ, Schaap MC, Berckmans RJ, Nieuwland R, Sturk A, van Doormaat FF, Meijers JC, Biemond BJ, CURAMA study group (2009) Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 94:1513–1519CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM (2005) Membrane microparticles: two sides of the coin. Physiology (Bethesda) 20:22–27CrossRefGoogle Scholar
  7. 7.
    Pattanapanyasat K, Gonwong S, Chaichompoo P, Noulsri E, Lerdwana S, Sukapirom K, Siritanaratkul N, Fucharoen S (2007) Activated platelet-derived microparticles in thalassaemia. Br J Haematol 136:462–471CrossRefPubMedGoogle Scholar
  8. 8.
    Nantakomol D, Palasuwan A, Chaowanathikhom M, Soogarun S, Imwong M (2012) Red cell and platelet-derived microparticles are increased in G6PD-deficient subjects. Eur J Haematol 89(5):423–429CrossRefPubMedGoogle Scholar
  9. 9.
    Dey-Hazra E, Hertel B, Kirsch T, Woywodt A, Lovric S, Haller H, Haubitz M, Erdbruegger U (2010) Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag 6(6):1125–1133PubMedPubMedCentralGoogle Scholar
  10. 10.
    Elsayh KI, Zahran AM, El-Abaseri TB, Mohamed AO, El-Metwally TH (2014) Hypoxia biomarkers, oxidative stress, and circulating microparticles in pediatric patients with thalassemia in upper Egypt. Clin Appl Thromb Hemost 20(5):536–545CrossRefPubMedGoogle Scholar
  11. 11.
    Eldor A, Rachmilewitz EA (2012) The hypercoagulable state in thalassemia. Blood 1(99):36–43Google Scholar
  12. 12.
    Pazgal I, Inbar E, Cohen M, Shilberg O, Stark P (2016) High indicence of silent cerebral infarcts in adult patients with beta thalassemia major. Throm Res 144:119–122CrossRefGoogle Scholar
  13. 13.
    Musallam KM, Taher AT, Karimi M, Rachmilewitz EA (2012) Cerebral infarction in beta thalassemia intermedia: breaking the silence. Thromb Res 130:695–702CrossRefPubMedGoogle Scholar
  14. 14.
    Karimi M, Toosi F, Haghpanah S, Pishdad P, Avazpour A, Rachmilewitz EA (2016) The frequency of silent cerabral ischemia in patients with transfusion dependent beta thalassemia major. Accepted for publication in Annals of Hematology 95:135–139CrossRefGoogle Scholar
  15. 15.
    Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP (2000) Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 111(2):467–473CrossRefPubMedGoogle Scholar
  16. 16.
    VanWijk MJ, VanBavel E, Sturk A, Nieuwland R (2003) Microparticles in cardiovascular diseases. Cardiovasc Res 59:277–287CrossRefPubMedGoogle Scholar
  17. 17.
    Tantawy AA, Adly AA, Ismail EA, Habeeb NM, Farouk A (2013) Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: relation to cardiovascular complications. Platelets 24(8):605–614CrossRefPubMedGoogle Scholar
  18. 18.
    Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A (2008) Elevated levels of circulating procoagulant micro-particles in patients with beta-thalassemia intermedia. Haematologica 93(6):941–942CrossRefPubMedGoogle Scholar
  19. 19.
    Taher A, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 115:1886–1892CrossRefPubMedGoogle Scholar
  20. 20.
    Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G (2005) Coagulation and splenectomy: an overview. Ann N Y Acad Sci 1054:317–324CrossRefPubMedGoogle Scholar
  21. 21.
    Atichartakarn V, Angchaisuksiri P, Aryurachai K, Onpun S, Chuncharunee S, Thakkinstian A, Atamasirikul K (2002) Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br J Haematol 118(3):893–898CrossRefPubMedGoogle Scholar
  22. 22.
    Cappellini MD, Motta I, Musallam KM, Taher A (2010) Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci 1202:231–236CrossRefPubMedGoogle Scholar
  23. 23.
    Zalloua PA, Shbaklo H, Mourad YA, Koussa S, Taher A (2003) Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb Haemost 89(4):767–768PubMedGoogle Scholar
  24. 24.
    Balla J, Vercellotti GM, Nath K, Yachie A, Nagy E, Eaton JW, Balla G (2003) Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol Dial Transplant 18(5):8–12CrossRefGoogle Scholar
  25. 25.
    Malyutin Z, Shai E, Dana M, Rachmilewitz E, Fibach E, VaronD (2012) Shorter carotid artery occlusion in a thalassemic mouse model: a potential role for oxidative stress affecting both RBCs and platelets. J Thromb Haemost 11:66–67Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Ilham Youssry
    • 1
  • Nohair Soliman
    • 2
  • Mona Ghamrawy
    • 1
  • Rania Mohamed Samy
    • 2
  • Amal Nasr
    • 2
  • Mohamed Abdel Mohsen
    • 1
  • Mohamed ElShahaat
    • 2
  • Rayan Bou Fakhredin
    • 3
  • Ali Taher
    • 3
  1. 1.Departments of Pediatrics, Faculty of MedicineCairo UniversityCairoEgypt
  2. 2.Clinical Pathology Department, Faculty of MedicineCairo UniversityCairoEgypt
  3. 3.Department of Internal MedicineAmerican University of Beirut Medical CenterBeirutLebanon

Personalised recommendations